New drug hope for rare nerve cancer: tazemetostat under study
NCT ID NCT04917042
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests the drug tazemetostat in 10 people with recurrent, treatment-resistant, or metastatic malignant peripheral nerve sheath tumors (MPNST), a rare and aggressive cancer. Participants take tazemetostat pills twice daily for up to 2 years. The main goal is to see if the drug can shrink tumors or stop them from growing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tazemetostat (TAZVERIK)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced MPNST, a rare and aggressive cancer.
What could go wrong
This is a small, early-phase trial with only 10 participants, so results may not apply broadly. The drug may not shrink tumors or improve survival, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL NERVE SHEATH TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Florida
Gainesville, Florida, 32608, United States